Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Device Start-Up News, September 2012

Executive Summary

This month we cover MxBiodevices LLC, which has completed two clinical trials of its injectable wound repair scaffold that is injected just under the wound surface to provide a healing structure; and Histogenics Corp., which is in a Phase III clinical trial in articular cartilage repair.

You may also be interested in...



Aiming For More Deals, Shire Christens Regenerative Medicine Unit

The company hopes its newest division will mirror the growth of its rare disease unit, which was built largely through aggressive business development.

Biologics: The Growth Engine in Advanced Wound Care

With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat.

Cartilage Repair: The Next Wave in Orthopedics

The musculoskeletal sector continues to be bogged down by the economic downturn, and particularly hard hit is the industry’s largest segment: the $13 billion total joint market. Companies are now scouting out the next technology wave in orthopedics, and the record attendance at the recent International Cartilage Repair Society meeting may be one indication of where the action will be for some time to come.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel